Do ADRB1 Arg389Gly and ADRB2 Arg16Gly variants change beta-adrenergic responsiveness?

Genetic variations in the beta-adrenergic receptors ADRB1 and ADRB2 are significant determinants of individual variability in cardiovascular responses to catecholamines and beta-adrenergic medications.

Clinical and hemodynamic evidence

Research indicates that polymorphisms in these genes directly influence heart rate and blood pressure regulation:

• ADRB1 (Arg389Gly): The Arg389 allele is associated with heightened sensitivity to sympathetic stimulation. Clinical studies show that individuals homozygous for Arg389 exhibit significantly greater increases in heart rate during dobutamine infusion and more pronounced responses to beta-blockers compared to Gly389 carriers.
• ADRB2 (Arg16Gly): The Gly16 variant is linked to altered vascular tone and blood pressure stability. Studies demonstrate that Gly16 carriers experience enhanced receptor downregulation, which can lead to impaired vasodilation and compensatory tachycardia. This variant is frequently associated with orthostatic intolerance and conditions like Postural Orthostatic Tachycardia Syndrome (POTS), where impaired beta-2 mediated vasodilation triggers sympathetic overactivity.

Mechanistic explanations

These physiological changes are driven by specific molecular interactions within the receptor pathways:

• Enhanced G-protein coupling: The ADRB1 Arg389 variant, located in the cytoplasmic helix 8, facilitates more efficient coupling with Gs-proteins. This results in accelerated activation kinetics and significantly higher production of cyclic AMP (cAMP) upon catecholamine binding compared to the Gly389 variant.
• Receptor desensitization: For ADRB2, the Gly16 variant promotes increased phosphorylation by G-protein receptor kinases (GRKs) and heightened recruitment of beta-arrestin. This molecular cascade leads to rapid receptor internalization and desensitization, effectively reducing the receptor's responsiveness during sustained adrenergic stress.

Bottom line

The ADRB1 rs1801253 and ADRB2 rs1042714 polymorphisms significantly alter beta-adrenergic receptor responsiveness. These variants dictate the intensity of heart rate and blood pressure changes in response to catecholamines, with ADRB1 primarily affecting cardiac contractility and ADRB2 influencing vascular regulation and receptor desensitization.